After 100 years of insulin as the cornerstone treatment for type 1 diabetes, the Type 1 Diabetes Grand Challenge hopes to revolutionise insulin therapy by investing £15 million through the Novel Insulins part of the Challenge.
This exciting new funding opportunity is designed to support transformative research in insulin development. This funding opportunity will make initial awards of up to £500,000 in phase 1. The call is open to academics in all fields as well as small to medium size biotechnology/pharmaceutical companies. There are NO geographical restrictions.
The deadline for submission of letters of intent is 17:00 GMT on 30 January 2024.
For more information, please visit the Type 1 Diabetes Grand Challenge website, where you will find the call text, application form, guidelines, and Terms & Conditions, or email SMFGrandChallenge@jdrf.org.uk.